



## **Copper-67 Labeled Bombesin Peptide for Targeted Radiotherapy of Prostate Cancer**

**Truc T. Huynh, Ellen M. van Dam, Sreeja Sreekumar, Cedric Mpoy, Benjamin J. Blyth, Fenella Muntz, Matthew J. Harris, and Buck E. Rogers**

<b>TABLE OF CONTENTS</b>	<b>Page</b>
Figure S1: HPLC chromatograms showing the [ <sup>67</sup> Cu]Cu-SAR-BBN	2
Figure S2: Radio-TLC chromatograms of [ <sup>67</sup> Cu]Cu-SAR-BBN in 50mM DTPA	3
Figure S3: Stability assays of [ <sup>67</sup> Cu]Cu-SAR-BBN	4
Figure S4: Body weight changes of PC-3 tumor-bearing mice injected with either saline (as control) or [ <sup>67</sup> Cu]Cu-SAR-BBN (n = 12, bars SEM)	5
Figure S5: Hematoxylin-Eosin (H&E) staining of kidneys, livers, and pancreas tissue slices with (A) Saline (as control) (B) [ <sup>67</sup> Cu]Cu-SAR-BBN	6
Figure S6: Proliferation heatmap of (A) Tumor #48C, Control (B) Tumor #41, [ <sup>67</sup> Cu]Cu-SAR-BBN	7
Table S1: Biodistribution report of [ <sup>67</sup> Cu]Cu-SAR-BBN in C57BL/6 female mice	8



**Figure S1: HPLC chromatograms showing the [ $^{67}\text{Cu}$ ]Cu-SAR-BBN.** Radio-HPLC analysis was performed with a mobile phase of water (0.1% TFA) and acetonitrile (0.1% TFA), 5–90% acetonitrile in 10:30 min, and elution was run with a 1 mL/min flow rate.



**Figure S2: Radio-TLC chromatograms of  $[^{67}\text{Cu}]\text{Cu-SAR-BBN}$  in 50mM DTPA .**







Figure S3: Stability assays of  $[^{67}\text{Cu}]\text{Cu-SAR-BBN}$ .



**Figure S4: Body weight changes of PC-3 tumor-bearing mice injected with either saline (as control) or [67Cu]Cu-SAR-BBN (n = 12, bars SEM). The doses were given on days indicated by dotted lines via tail vein. The data represents the mean percent weight change from baseline (day 1) for each group.**



**Figure S5: Hematoxylin-Eosin (H&E) staining of kidneys, livers, and pancreas tissue slices with (A) Saline (as control) (B) [ $^{67}\text{Cu}$ ]Cu-SAR-BBN.**



**Figure S6: Proliferation heatmap of (A) Tumor #48C, Control (B) Tumor #41,  $[^{67}\text{Cu}]\text{Cu-SAR-BBN}$ .** Control group tumors contain limited areas of poor cellularity/necrosis (black zones), large areas of tumor with moderate proliferation (sparse red/blue signal) and high proliferation areas at the periphery (intense red signal).  $[^{67}\text{Cu}]\text{Cu-SAR-BBN}$  treated tumors contain extensive areas of necrosis (black zones), limited areas of surviving tumor with limited proliferation (sparse red/blue signal) and high proliferation areas at the periphery (intense red signal).

**Table S1: Biodistribution report of [<sup>67</sup>Cu]Cu-SAR-BBN in C57BL/6 female mice.**

	1 h		2 h		4 h		6 h	
	%ID/g	SD	%ID/g	SD	%ID/g	SD	%ID/g	SD
<b>Blood</b>	1.06	0.18	0.62	0.19	0.53	0.17	0.54	0.13
<b>Lung</b>	2.75	0.28	1.95	0.68	2.68	0.81	3.25	0.72
<b>Liver</b>	7.21	1.05	5.08	1.31	5.90	1.25	6.78	1.31
<b>Spleen</b>	1.94	0.72	1.27	0.37	0.94	0.15	0.90	0.12
<b>Kidney</b>	6.15	0.73	3.99	0.95	3.48	0.75	3.53	0.68
<b>Muscle</b>	0.52	0.17	0.25	0.10	0.35	0.07	0.59	0.63
<b>Bone</b>	0.88	0.14	0.40	0.12	0.47	0.12	0.46	0.14
<b>Heart</b>	1.00	0.10	0.58	0.21	0.78	0.28	0.84	0.22
<b>Pancreas</b>	22.32	10.54	14.71	5.43	5.48	0.73	3.38	0.80
	24 h		72 h		6 days		9 days	
	%ID/g	SD	%ID/g	SD	%ID/g	SD	%ID/g	SD
<b>Blood</b>	0.33	0.16	0.39	0.04	0.11	0.03	0.06	0.03
<b>Lung</b>	1.81	0.72	1.89	0.17	0.68	0.16	0.32	0.12
<b>Liver</b>	3.80	1.36	4.03	0.28	1.31	0.28	0.59	0.24
<b>Spleen</b>	0.51	0.20	0.74	0.08	0.30	0.07	0.14	0.05
<b>Kidney</b>	2.37	0.80	3.10	0.10	1.37	0.34	0.74	0.20
<b>Muscle</b>	0.20	0.11	0.27	0.04	0.21	0.07	0.15	0.04
<b>Bone</b>	0.31	0.22	0.25	0.16	0.09	0.03	0.09	0.03
<b>Heart</b>	0.84	0.42	1.35	0.29	0.93	0.28	0.58	0.20
<b>Pancreas</b>	0.55	0.27	0.75	0.11	0.39	0.09	0.22	0.06